Dr. Lal Path Labs · tone and specificity signals across the available quarters.
Language signals
Revenue growth rate is the highest quarterly growth rate achieved in the last four years. The revenue growth is mainly driven by patient volumes which stood at 8.22 million with a growth of 8.2% and sample volumes which stood at 25.9 million with a growth of 10.7%.
Our assessment is that CGHS EC HS price increase is in fact extremely to the tune between 2 to 3% at an overall company level and I think this benefit will continue for at least another two to three quarters.
The idea always is to reinvest for future growth. We would be leaning towards investing more back into business. We will be looking at Q2 more closely before any of those decisions can be taken.
We are confident that we should be able to deliver between 11 to 12% for the year.
We are hopeful that we can maintain the trajectory between 27 to 28%.
I definitely don't see a price increase on the horizon at least or not for the next two to three quarters.